Dr. Drake On The Role of Cytoreductive Nephrectomy In RCC
Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia ’s Cancer Immunotherapy Programs, discusses the role of cytoreductive nephrectomy in the treatment of patients with renal cell carcinoma (RCC).08/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 8, 2018 Category: Urology & Nephrology Source Type: news

New Evidence May Help Improve Management Of Rare Kidney Cancers
Researchers have identified relapse patterns of nonclear cell renal cell carcinomas — an understudied group of rare kidney cancers — that are distinct from the more common clear cell renal cell carcinomas. The findings may help improve the management of patients with nonclear cell renal cell carcinomas (non-ccRCC), who represent approximately 20 percent of kidney cancer patien t populations.08/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 8, 2018 Category: Urology & Nephrology Source Type: news

Young Mother Has Hope and Health After a New Technique for Treating Kidney Cancer
Twenty-two weeks into her third pregnancy, Jessica Dykstra experienced incredible joy and intense fear --- in just a few minutes. Jessica learned she was having a baby girl to complement her two toddler boys. And just minutes before, the 25-year-old San Diego resident was diagnosed with stage 2 renal cell carcinoma — a malignant tumor on her left kidney.08/07/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 7, 2018 Category: Urology & Nephrology Source Type: news

Cytoreductive Nephrectomy May Still Remain Standard For Some With Metastatic Renal Cell Carcinoma
The addition of cytoreductive nephrectomy to treatment with sunitinib malate did not provide a survival benefit for intermediate and poor-risk patients with metastatic renal cell carcinoma, according to results of the phase 3 CARMENA clinical trial presented at ASCO Annual Meeting.08/06/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 6, 2018 Category: Urology & Nephrology Source Type: news

Certain Renal Cancer Subtypes Linked to Obesity
Obesity is associated with development of clear cell and possibly chromophobe renal cell carcinoma (RCC), but not papillary RCC, according to researchers.07/31/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 31, 2018 Category: Urology & Nephrology Source Type: news

Combined assessment of low PGRMC1/positive ATP1A1 levels has enhanced prognostic value for renal cell carcinoma
Progesterone receptor membrane component 1 (PGRMC1) and Na+/K+ ‑ATPase α1 subunit (ATP1A1) are two proteins associated with the clinical prognosis of renal cell carcinoma (RCC) and RCC cell proliferation. However, the two proteins have been previously studied independently, and their combined influence on the clinical outcome of RCC remains unclear.07/27/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 27, 2018 Category: Urology & Nephrology Source Type: news

Sexual Disorders of Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Antiangiogenic Therapies
Targeted therapies, in particular antiangiogenic therapies (AATs), have become the standard of treatment for metastatic renal cell carcinoma (mRCC). Although common adverse effects like fatigue have been well-established, sexual disorders induced by these treatments, although often reported, have been poorly evaluated.07/27/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 27, 2018 Category: Urology & Nephrology Source Type: news

Efficacy of Nivolumab in a Patient with Metastatic Renal Cell Carcinoma and End-Stage Renal Disease on Dialysis
Treatment of patients with metastatic renal cell carcinoma (mRCC) and end-stage renal disease (ESRD) on dialysis poses a therapeutic challenge, particularly as this patient group was excluded from the pivotal clinical trials. In addition, there is uncertainty regarding drug dosing/pharmacokinetics, lack of safety and efficacy data, and potential for increased toxicity when using targeted therapy or immunotherapy for the management of patients with mRCC on dialysis.07/25/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 25, 2018 Category: Urology & Nephrology Source Type: news

Comprehensive analysis of a novel lncRNA profile reveals potential prognostic biomarkers in clear cell renal cell carcinoma
Clear cell renal cell carcinoma (ccRCC) is the main subtype of malignant kidney cancer. Long non ‑coding RNA (lncRNA) serves a key role in predicting survival in patients with cancer.07/25/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 25, 2018 Category: Urology & Nephrology Source Type: news

VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma
Studies show that ZHX2 could be used as a potential therapeutic target for ccRCC.07/20/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 23, 2018 Category: Urology & Nephrology Source Type: news

Mesothelioma Case Report Touts Success with Opdivo
Not every mesothelioma patient benefits from the immunotherapy drug Opdivo, but for the ones that do, the response can be lifesaving. Opdivo, known generically as nivolumab, continues to produce dramatic results, inching it closer to FDA approval for mesothelioma cancer. A recently published individual case report describes “an exceptional and sustained response.” Treatment with Opdivo allowed one patient to go from a downward spiral, with only weeks to live, back into the workforce. “We were blown away by the patient’s response,” lead author Riley Jones, now in his fellowship at the Universit...
Source: Asbestos and Mesothelioma News - July 23, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Renal cell cancer risk after kidney transplantation
This study shows the risk of RCC after kidney transplantation.07/19/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 19, 2018 Category: Urology & Nephrology Source Type: news

Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma
In a study reported in JAMA Oncology, Carlo et al found a high prevalence of germline mutations in cancer susceptibility genes in patients with advanced renal cell carcinoma (RCC).07/19/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 19, 2018 Category: Urology & Nephrology Source Type: news

Acute Kidney Injury in Patients With Cancer
Acute kidney injury (AKI) is a common complication in cancer patients and occurs in up to 30% of patients during their disease course. Multiple myeloma, leukemia/lymphoma, renal cell carcinoma, and hematopoietic stem cell transplantation are commonly associated with the development of AKI.07/19/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 19, 2018 Category: Urology & Nephrology Source Type: news

Discovery of kidney cancer driver could lead to new treatment strategy
(UNC Lineberger Comprehensive Cancer Center) In a study published in the journal Science, researchers suggest that ZHX2 is a potential new therapeutic target for clear cell renal cell carcinoma, which is the most common type of kidney cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 19, 2018 Category: International Medicine & Public Health Source Type: news

VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma
Inactivation of the von Hippel-Lindau (VHL) E3 ubiquitin ligase protein is a hallmark of clear cell renal cell carcinoma (ccRCC). Identifying how pathways affected by VHL loss contribute to ccRCC remains challenging. We used a genome-wide in vitro expression strategy to identify proteins that bind VHL when hydroxylated. Zinc fingers and homeoboxes 2 (ZHX2) was found as a VHL target, and its hydroxylation allowed VHL to regulate its protein stability. Tumor cells from ccRCC patients with VHL loss-of-function mutations usually had increased abundance and nuclear localization of ZHX2. Functionally, depletion of ZHX2 inhibited...
Source: ScienceNOW - July 19, 2018 Category: Science Authors: Zhang, J., Wu, T., Simon, J., Takada, M., Saito, R., Fan, C., Liu, X.-D., Jonasch, E., Xie, L., Chen, X., Yao, X., Teh, B. T., Tan, P., Zheng, X., Li, M., Lawrence, C., Fan, J., Geng, J., Liu, X., Hu, L., Wang, J., Liao, C., Hong, K., Zurlo, G., Parker, J Tags: Cell Biology, Medicine, Diseases reports Source Type: news

Better Metastatic Renal Cell Carcinoma Survival at Higher-Volume Facilities Better Metastatic Renal Cell Carcinoma Survival at Higher-Volume Facilities
Patients with metastatic renal cell carcinoma (mRCC) treated at higher-volume facilities survive longer than those treated at lower-volume facilities, according to a registry-based analysis.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 16, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

A Call for Better Screening for Hereditary Renal Cell Carcinoma
It may be time to adopt a broader approach to tumor and matched normal sequencing in patients with advanced renal cell carcinoma (RCC), according to a large new study.07/13/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 13, 2018 Category: Urology & Nephrology Source Type: news

Anastomosing hemangioma of the kidney: radiologic and pathologic distinctions of a kidney cancer mimic
Anastomosing hemangioma (ah) is a rare subtype of primary vascular tumour that can, clinically and radiologically, present similarly to malignant renal tumours such as renal cell carcinoma (rcc) and angiosarcoma.07/12/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 12, 2018 Category: Urology & Nephrology Source Type: news

A Call for Better Screening for Hereditary Renal Cell Carcinoma
More than 20% of patients with non –clear cell RCC had a germline mutation, and half of this group could benefit from direct systemic therapy. (Source: CancerNetwork)
Source: CancerNetwork - July 12, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Targeting tumor-associated acidity in cancer immunotherapy
Checkpoint inhibitors, such as cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) and programmed cell death-1 (PD-1) monoclonal antibodies have changed profoundly the treatment of melanoma, renal cell carcinoma, non-small cell lung cancer, Hodgkin lymphoma, and bladder cancer. Currently, they are tested in various tumor entities as monotherapy or in combination with chemotherapies or targeted therapies. However, only a subgroup of patients benefit from checkpoint blockade (combinations).07/11/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 11, 2018 Category: Urology & Nephrology Source Type: news

Immune Checkpoint Blockade in Advanced Renal-Cell Carcinoma
In the CheckMate 214 trial, Motzer et al found higher overall survival among intermediate- and poor-risk patients with previously untreated metastatic renal-cell carcinoma who received nivolumab plus ipilimumab than among those who received sunitinib07/05/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 10, 2018 Category: Urology & Nephrology Source Type: news

Research Reveals Immunotherapy More Effective in Men
For mesothelioma patients, immunotherapy is mostly available through clinical trials at this time. Immunotherapy is a relatively new way to treat cancer, and doctors still are learning who will respond best to these novel therapies. Newly released medical research has found men seem to respond better to immunotherapy than women. But this doesn’t mean immunotherapy is off the table for women with mesothelioma. You should learn all you can about how immunotherapy works, why it may or may not be right for you and how you can best prepare yourself if you decide an immunotherapy clinical trial is right for you. Thorough ...
Source: Asbestos and Mesothelioma News - July 3, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Ablation, Not Surgery, for Some Small Renal Tumors Ablation, Not Surgery, for Some Small Renal Tumors
Percutaneous ablation can be an alternative to surgery in appropriate patients with small early renal cell carcinoma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 28, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Dr. Pal Discusses the Role of PD-L1 in Metastatic RCC
Sumanta Kumar Pal, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses the role of PD-L1 in metastatic renal cell carcinoma (RCC). One of the biggest unanswered questions in the frontline setting of metastatic RCC is the role of PD-L1. Pal says that there is more to the PD-L1 story, particularly considering the findings of the CheckMate-214 trial. There was a clear difference in clinical outcomes for patients who were PD-L1– positive versus PD-L1–negative, Pal explains. Whether that is clinically applicable is ...
Source: Kidney Cancer Association - June 28, 2018 Category: Urology & Nephrology Source Type: news

Altering Gut Microbiome May Improve ICI Outcomes in RCC
John SchieszerJun 5, 2018Making some changes to the gut microbiome may improve outcomes with immune checkpoint inhibitors in renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 5, 2018 Category: Cancer & Oncology Authors: A Source Type: news

ASCO: Sunitinib Alone Noninferior in Metastatic Renal Cell Cancer
Sunitinib alone noninferior to nephrectomy plus sunitinib with respect to overall survival (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 5, 2018 Category: Cancer & Oncology Tags: Nephrology, Oncology, Pharmacy, Surgery, Conference News, Source Type: news

ASCO: Sunitinib Alone Noninferior in Metastatic Renal Cell Cancer
MONDAY, June 4, 2018 -- For patients with metastatic renal cell carcinoma classified as having intermediate or poor prognostic risk, sunitinib alone is noninferior to nephrectomy and sunitinib, according to a study published online June 3 in the New... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 4, 2018 Category: Pharmaceuticals Source Type: news

In Advanced Kidney Cancer, Surgery No Longer Standard of Care In Advanced Kidney Cancer, Surgery No Longer Standard of Care
The management of patients with metastatic renal cell carcinoma has changed with the advent of targeted therapy. Now a major clinical trial indicates that those drugs alone are sufficient for many of these patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 3, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

In Advanced Kidney Cancer, Surgery No Longer Sole Standard of Care In Advanced Kidney Cancer, Surgery No Longer Sole Standard of Care
The management of patients with metastatic renal cell carcinoma has changed with the advent of targeted therapy. Now a major clinical trial indicates that those drugs alone are sufficient for many of these patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 3, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Many With Metastatic Kidney Cancer Can Forego Surgery
Bryant FurlowJun 3, 2018For many patients diagnosed with metastatic renal cell carcinoma, sunitinib alone is not inferior to surgery followed by sunitinib. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Nektar And Bristol Hurtle Forward With Experimental Cancer Drug
Nektar Pharmaceuticals and Bristol-Myers Squibb said results for their experimental cancer drug, NKTR-214, pushing forward into late-stage trials testing the medicine against melanoma, renal cell carcinoma, and urothelial cancer. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - June 2, 2018 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NASDAQ:NKTR NYSE:BMY Source Type: news

Depleted metabolic enzymes promote tumor growth in kidney cancer
(University of Pennsylvania School of Medicine) By integrating data on the function of essential metabolic enzymes with genetic, protein, and metabolic abnormalities associated with " clear cell " renal cell carcinoma (ccRCC), researchers have determined that enzymes important in multiple pathways are universally depleted in ccRCC tumors. Kidney cancer, one of the ten most prevalent malignancies in the world, has increased in incidence over the last decade, likely due to rising obesity rates. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 10, 2018 Category: Cancer & Oncology Source Type: news

Patient and Tumor Features Predicted RCC Outcomes Post Nephrectomy
Routinely available patient and tumor features accurately predicted the risk progression and death from RCC post nephrectomy, a Mayo Clinic team found. (Source: CancerNetwork)
Source: CancerNetwork - May 9, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

Type 2 Diabetes Ups Risk of Renal Cancer in Women, but Not Men
TUESDAY, May 8, 2018 -- Type 2 diabetes is independently associated with a greater risk of renal cell carcinoma (RCC) in women, but not in men, according to a study published online April 20 in Diabetes Care. Rebecca E. Graff, Sc.D., from Harvard... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 8, 2018 Category: Pharmaceuticals Source Type: news

NSAID Use Associated With Shorter PFS, OS in Metastatic RCC
A pooled retrospective analysis of nearly 5,000 mRCC patients in phase II and III trials showed PFS among NSAIDs users was half that of NSAIDs nonusers. (Source: CancerNetwork)
Source: CancerNetwork - May 7, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: News Renal Cell Carcinoma Source Type: news

New CABOSUN Data Show Better PFS With Cabozantinib in mRCC
The significantly better PFS compared with sunitinib supports cabozantinib as initial therapy for patients with advanced RCC of intermediate or poor risk. (Source: CancerNetwork)
Source: CancerNetwork - May 3, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: News Renal Cell Carcinoma Source Type: news

When TKI Sunitinib Can Be Discontinued in Metastatic RCC When TKI Sunitinib Can Be Discontinued in Metastatic RCC
Can sunitinib be discontinued in patients with stable metastatic renal cell carcinoma without negatively impacting outcomes?Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 2, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Use of ibuprofen and similar NSAIDs may shorten life of patients
(IOS Press) Ibuprofen, aspirin, and other non-steroidal anti-inflammatory medications are among the most commonly utilized medications in the United States. Primarily for treating pain, inflammation, and preventing cardiovascular disease, NSAIDs' promising anti-cancer properties have been highlighted by a growing body of data in recent years. However, a new study in the journal Kidney Cancer indicated that non-aspirin NSAID use was associated with shorter overall survival in patients with metastatic renal cell carcinoma (mRCC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 1, 2018 Category: International Medicine & Public Health Source Type: news

What Causes Flushing?
Discussion Flushing is usually thought of as a benign condition such as blushing, but can be quite irritating if it is frequent or persistent (i.e. menopausal hot flashes) or even pathologic (i.e. malignancy). “Flushing is a subjective and sensation of warmth that is accompanied by reddening of the skin anywhere on the body but favors the face, neck, and upper torso…. Flushing can be broadly divided into episodic or persistent. Episodic flashing is mediated by the release of endogenous vasoactive mediators or medications, while persistent flushing result in a fixed facial erythema with telangiectasias and cyan...
Source: PediatricEducation.org - April 30, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Preferred First-line Treatment for Metastatic Kidney Cancer Preferred First-line Treatment for Metastatic Kidney Cancer
Indirect comparisons suggest that of available agents, cabozantinib or nivolumab plus ipilimumab may be the most effective first-line treatment for metastatic renal-cell carcinoma.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 27, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Nivolumab/Ipilimumab Combo Approved for Advanced RCC
In a pivotal trial, combination of nivolumab and ipilimumab yielded improvement in OS and ORR of poor-risk RCC patients. (Source: CancerNetwork)
Source: CancerNetwork - April 19, 2018 Category: Cancer & Oncology Authors: Dylan Fisher Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

FDA approves combination for advanced renal cell carcinoma
The approvals were based on CheckMate 214 (NCT02231749), a randomized open-label trial. Patients with previously untreated advanced RCC received nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) every 3 weeks for 4 doses followed by nivolumab monotherapy (3 mg/kg) every 2 weeks, or sunitinib 50 mg daily for 4 weeks followed by 2 weeks off every cycle.04/17/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 17, 2018 Category: Urology & Nephrology Source Type: news

Antibiotics Reduced Efficacy of Checkpoint Inhibitors in RCC, NSCLC
Antibiotics administered within 30 days of starting immunotherapy reduced both PFS and OS for patients with advanced RCC and NSCLC. (Source: CancerNetwork)
Source: CancerNetwork - April 16, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

FDA Approves IO Combo for Advanced Renal Cell Cancer FDA Approves IO Combo for Advanced Renal Cell Cancer
The approval of the nivolumab and ipilimumab combination provides a new first-line treatment option for a segment of patients with advanced renal cell carcinoma.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 16, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) Combination as First-Line Treatment for Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma
PRINCETON, N.J.--(BUSINESS WIRE) April 16, 2018 --Bristol-Myers Squibb Company (NYSE: BMY) today announced that Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) was approved by the U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 16, 2018 Category: Drugs & Pharmacology Source Type: news

Nivolumab/Ipilimumab Combo Bests Sunitinib in Advanced RCC
A phase III study by Dr. Robert Motzer and colleagues in NEJM found significantly higher OS and ORRs with the immunotherapy combination. (Source: CancerNetwork)
Source: CancerNetwork - April 9, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Immuno Oncology News Renal Cell Carcinoma Source Type: news

Payments to doctors linked to prescription practices for two cancer types
(UNC Lineberger Comprehensive Cancer Center) Compared to physicians who didn't receive any payments, those who received general payments for meals and lodging from a drug manufacturer had higher odds of prescribing that company's particular drug for metastatic renal cell carcinoma and for chronic myeloid leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 9, 2018 Category: Cancer & Oncology Source Type: news

First-Line Avelumab/Axitinib Encouraging in Advanced RCC
First-line combination therapy with the PD-L1 inhibitor avelumab and the VEGFR TKI axitinib yielded antitumor activity in previously untreated RCC. (Source: CancerNetwork)
Source: CancerNetwork - April 5, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

Combinations: The Future of Renal Cell Carcinoma Treatment?
Renal cell carcinoma (RCC) is the most common form of kidney cancer, with an estimated 65,340 patients expected to be diagnosed in 2018 in the United States alone. Nearly a third of those patients will be diagnosed with the advanced or metastatic disease.04/05/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 5, 2018 Category: Urology & Nephrology Source Type: news